Why Solid Biosciences Inc.’s (SLDB) Stock Is Up 7.43%
As of Tuesday, October 20, Solid Biosciences Inc.’s SLDB share price has surged by 7.43%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Commentary & Analysis
Why Solid Biosciences Inc.’s (SLDB) Stock Is Up 5.06%
As of Monday, October 19, Solid Biosciences Inc.’s SLDB share price has surged by 5.06%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Solid Biosciences Inc.’s (SLDB) Stock Is Down 7.00%
As of Tuesday, October 13, Solid Biosciences Inc.’s SLDB share price has dipped by 7.00%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Solid Biosciences Inc.’s (SLDB) Stock Is Down 6.05%
As of Thursday, September 24, Solid Biosciences Inc.’s SLDB share price has dipped by 6.05%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Solid Biosciences Inc.’s (SLDB) Stock Is Down 6.00%
As of Wednesday, September 23, Solid Biosciences Inc.’s SLDB share price has dipped by 6.00%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | SLDB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $663.7 | $229.3 | 41% |
|
| Shares Out (Mil) | 143.7 | 53.4 | 70% |
|
| Institutional Ownership | 98.7% | 92.9% | 81% |
|
| Float (Mil) | 64.8 | 41.4 | 52% |
|
| Beta | 2.42 | 0.94 | 95% |
|
| Avg Daily Volume (000s) | 1,569 | 533 | 78% |
|
| Price Change (52-week) |
3.0% | 47.5% | 55% |
|
| Growth | SLDB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (14.6%) | (10.1%) | 26% |
|
| EPS (5yr) | 39.9% | 15.8% | 89 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.0%) | (15.7%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 14 | 14 | 14 | |
| Current EPS | ($0.413) | ($1.756) | ($1.710) | |
| Month Ago EPS | ($0.413) | ($1.761) | ($1.732) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.475) | ($1.957) | ($1.958) | |
| Year/Year Chg | 8.4% | (11.8%) | (36.4%) | |
| Financials | SLDB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($207) | ($44) | 6% |
|
| EPS (TTM) | ($1.870) | ($1.600) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($187) | ($34) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $20 | $3 | 62% |
|
| Long-Term Debt (Q1) (Mil) | $18 | $4 | 32% |
|
| Enterprise Value (Q1) (Mil) | $640 | $179 | 36% |
|
| Valuation | SLDB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.74 | 2.17 | 48% |
|
| P/E | na | 20.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | SLDB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (56.8%) | (47.1%) | 10% |
|
| ROE | (65.5%) | (53.5%) | 13% |
|
| Liabilities to Assets | 11.1% | 29.3% | 7% |
|
| F-Score | 4 | 2 | 33% |
|
Solid Biosciences Inc. did not pass any screens on 10/22/2026.
